



FOR IMMEDIATE RELEASE

Contact:
Paul Byerley
Chief Executive Officer
+1 320.259.4321
pbyerley@artossinc.com

Artoss, Inc. Announces Appointment of Eugene "Gene" Champeau to its Board of Directors

Board Experience Supports NanoBone U.S. Commercialization Efforts

St. Cloud, MN, March 25, 2021 / -- Artoss, Inc. (St. Cloud, MN), a medical device company that is pioneering the use of advanced bone graft substitutes to treat multiple orthopaedic indications, announced the appointment of Eugene "Gene" Champeau to its Board of Directors. Gene has extensive medical device leadership experience and will provide the Management Team with engagement and assistance in meeting commercial objectives.

Gene is a well-respected medical device entrepreneur and executive with over 30 years of experience in implantable and interventional devices. Paul Byerley, President and Chief Executive Officer (CEO) of Artoss, Inc., the exclusive North American distributor for NanoBone in orthopaedic surgery, stated, "Gene has a wealth of experience in building and managing medical device organizations, including NeoMetrics, which commercializes specialty guidewires for interventional procedures, and was acquired by Heraeus Medical Components. We're pleased that Gene is joining our Team, which has the best standalone synthetic bone graft on the market."

"I am pleased to join the Artoss, Inc. Board and assist Paul Byerley and Jim Cassidy to continue NanoBone sales momentum," said Gene. "I have been in the medical device world over 30 years and rarely seen impressive standalone products, such as NanoBone. I look forward to working alongside my fellow Board members and Company Management to advance NanoBone commercially." In addition to Paul and Jim, Gene joins with experienced Board Members Charles Emley and Gilbert Ortega, MD, both highly respected, with Charles, a seasoned executive, and Gilbert, a renowned orthopaedic trauma surgeon.

NanoBone has consistent and cost-effective outcomes in bone grafting in multiple orthopaedic indications. NanoBone achieves these outcomes with no preparation required, excellent handling for surgeons, creation of an osteogenic matrix within 14 days, and clinical and radiographic healing in as little as 8 weeks. The dramatic growth in NanoBone procedures further secures its growing market position as a leader in the bone repair space. There is growing acceptance by surgeons that not all bone graft substitutes are the same, given the rapid osteogenic matrix formation of NanoBone within 14 days.

###

About NanoBone

NanoBone was first cleared by the Food and Drug Administration (FDA) in 2015 after having been successfully used in Europe for ten years. Clinical publications have identified bone graft substitutes as an increasingly important component of many orthopaedic procedures. Consistent healing in orthopaedic procedures is a significant unmet clinical need and one where NanoBone may provide an effective option.

NanoBone is a commercially available product in the U.S. intended to fill bony voids or gaps of the skeletal system (i.e., extremities, posterolateral spine and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NanoBone[®] SBX Putty resorbs and is replaced with bone during the healing process.

###

About Artoss, Inc.

Artoss, Inc. (St. Cloud, MN) is a medical device company that is a leading distributor of bioidentical bone graft substitutes to treat multiple orthopaedic indications and is dedicated to the development of tools and products for effectively treating a variety of orthopaedic conditions requiring surgical intervention. The company markets, NanoBone Bone Graft Substitute, which gives clinical outcomes comparable to autograft with less postoperative pain and complications. Artoss, Inc. has an experienced management team with extensive experience in orthopaedic medical devices.